Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514371 · ClinicalTrials.gov registry record · Phase 2
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00514371 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT00514371, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
Interventions
- DRUG Bortezomib
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514371
The ClinicalTrials.gov registry entry for NCT00514371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT00514371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514371 about?
NCT00514371 is a clinical study titled "A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma". This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
What is the current status of trial NCT00514371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2007-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00514371?
The interventions under investigation include: Bortezomib (DRUG), tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00514371?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.